Your session is about to expire
← Back to Search
64Cu-FBP8 PET-CT Imaging for Blood Clots
Study Summary
This trial will test a new imaging tool to help diagnose PE and DVT by looking for fresh clots in the vascular system.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I cannot lie flat for 45 minutes due to a condition like back pain or arthritis.My eligibility is not affected by my race, sex, or ethnicity.I am not pregnant or breastfeeding, confirmed by a test.I am 18 or older and have a confirmed pulmonary embolism.I have a condition or take medication that may increase my risk in this study.You weigh more than 300 kilograms, which is the maximum weight the PET camera table can support.My scan for blood clots was over 3 days ago.I received a special injection within 3 days of being diagnosed.I am not pregnant, trying to get pregnant, or have a positive pregnancy test.I need increasing doses of medication to maintain my blood pressure.My kidney function is good, with an eGFR of 30 or higher.I am under 18 years old.
- Group 1: Acute pulmonary embolism
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research endeavor presently open to new participants?
"Indeed, the clinicaltrials.gov website confirms that enrollment is ongoing for this medical study which was initially listed on May 13th 2019. As of July 15th 2019, 80 participants are needed to be recruited from a single site."
Has the 64Cu-FBP8 drug been authorized by the FDA?
"Our team at Power judged the safety of 64Cu-FBP8 to be a 1 because this is an early stage trial. Thus, there exists marginally supporting evidence for efficacy and barely any regarding potential risks."
What is the cap on the number of participants involved in this medical research?
"Affirmative. Clinicaltrials.gov's data confirms that this clinical research is actively recruiting participants; a process which began on May 13th, 2019 and was most recently updated 15 July 2019. 80 volunteers are being sought from 1 medical centre for the study."
Share this study with friends
Copy Link
Messenger